Advertisement

Phosphatidylcholine Biosynthesis as a Target for Phospholipid Analogues

  • Christoph C. Geilen
  • Thomas Wieder
  • Constantin E. Orfanos
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 416)

Abstract

In current anticancer therapies, most cytostatic agents impair cell division by crosslinking DNA (e.g. cis-platin or alkylating agents), disrupting the cytoskeleton (e.g. vinblastine) or rectifying the cytoskeleton (e.g. taxol). In a new approach to cancer chemotherapy, the cell membrane was described as a target for cytostatic agents. It is known that alkyl-lysophospholipids possess antineoplastic properties in vitro and in vivo1, leading to the development of an other class of antiproliferative phospholipid analogues, the alkylphosphocholines. One of these phospholipid analogues, hexadecylphosphocholine (HePC), has been shown to inhibit cell proliferation and tumour growth 2–4.

Keywords

HaCaT Cell Choline Chloride Cytostatic Agent German Cancer Research Mock Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Berdel, W. E., Andreesen, R., and Munder, P.G. (1985) in Phospholipids and cellular Regulation Kuo, J. F. et. al. Vol. 2, pp. 41–73, CRC Press, Boca Raton, FL.Google Scholar
  2. 2.
    Unger, C., Fleer. E.A.M., Kötting, J., Neumüller, W., and Eibl, H. (1992) Prog. Exp. Tumor Res. 34: 25–32.PubMedGoogle Scholar
  3. 3.
    Geilen, C. C., Haase, R., Buchner, K., Wieder, Th., Hucho, F., and Reutter, W. (1991) Eur. J. Cancer 27, 1650–1653.PubMedCrossRefGoogle Scholar
  4. 4.
    Unger, C., Eibl, H., Breiser, H.W., van Heyden, H.W., Engel, J., Hilgard, R, Sindermann, H., Peukert, M., and Nagel, G.S. (1988) Onkologie 11: 295–296.PubMedCrossRefGoogle Scholar
  5. 5.
    Haase, R., Wieder, Th., Geilen, C.C., and Reutter, W. (1991) FEBS Lett. 288, 129–132.PubMedCrossRefGoogle Scholar
  6. 6.
    Geilen, C.C., Wieder, Th., and Reutter, W. (1992) J. Biol. Chem. 267, 6719–6724.PubMedGoogle Scholar
  7. 7.
    Wieder, Th., Geilen, C. C., and Reutter, W. (1993) Biochem. J. 291, 561–567.PubMedGoogle Scholar
  8. 8.
    Detmar, M., Geilen, C.C., Wieder, Th., Orfanos, C.E., and Reutter, W. (1994) J. Invest. Dermatol. 102: 490–494.PubMedCrossRefGoogle Scholar
  9. 9.
    Wieder, Th., Haase, A., Geilen, C.C., and Orfanos, C.E. (1995) Lipids 30: 389–393.PubMedCrossRefGoogle Scholar
  10. 10.
    Geilen, C.C., Haase, A., Wieder, Th., Arndt, D., Zeisig, R., and Reutter, W. (1994) J. Lipid Res. 35: 625–632.PubMedGoogle Scholar
  11. 11.
    Wieder, Th., Perlitz, C., Wieprecht, M., Huang, R.T.C., Geilen, C.C., ans Orfanos, C.E. (1995) Biochem. J., in press.Google Scholar
  12. 12.
    Boggs, K.P., Rock, C.O., and Jackowski, S. (1995) J. Biol. Chem. 270: 7757–7764.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Christoph C. Geilen
    • 1
  • Thomas Wieder
    • 1
  • Constantin E. Orfanos
    • 1
  1. 1.Department of DermatologyUniversity Medical Center Benjamin Franklin The Free University of BerlinBerlinGermany

Personalised recommendations